Empagliflozin & Linagliptin Tablets (EMPAGIL-25/5)

Empagliflozin & Linagliptin Tablets (EMPAGIL-25/5)

EMPAGIL 25 (Empagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, which works by blocking the reabsorption of glucose in the kidneys, promoting its excretion in the urine, and reducing blood glucose levels.

# Benefits over other Antidiabetic Drugs, Empagliflozin has several benefits over other antidiabetic drugs, including:

- Cardiovascular Benefits: Empagliflozin has been shown to reduce the risk of cardiovascular events, such as heart attacks, strokes, and deaths, in patients with type 2 diabetes.

- Weight loss: Empagliflozin can lead to weight loss, which is beneficial for patients with type 2 diabetes.

- Blood Pressure Reduction: Empagliflozin has been shown to reduce blood pressure in patients with type 2 diabetes.